Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Mar 13;17(3):e80527.
doi: 10.7759/cureus.80527. eCollection 2025 Mar.

Escalating Doses of Buprenorphine for the Treatment of Buprenorphine-Induced Opioid Withdrawal

Affiliations
Case Reports

Escalating Doses of Buprenorphine for the Treatment of Buprenorphine-Induced Opioid Withdrawal

Steven J Laxton. Cureus. .

Abstract

This report outlines a case of opiate withdrawal that occurred following the initiation of treatment for opioid use disorder (OUD) with buprenorphine. Buprenorphine is a novel drug that is used in the treatment of OUD and is incredibly effective in doing so. However, a rare and paradoxical effect can occur when treatment is initiated with buprenorphine, where the drug, due to its unusual mechanism of action, precipitates withdrawal. Most of the time, withdrawal can be treated with supportive therapy. However, there is growing evidence in the literature that withdrawals precipitated by buprenorphine can and should be treated with increased doses of buprenorphine. This case is an example of this exact phenomenon. In this case, our patient had a longstanding OUD, particularly fentanyl use, which was treated the day of presentation with the initiation of buprenorphine. She later presented to the emergency department in opioid withdrawal, which was treated with adjunct therapy that did not aid in the resolution of symptoms. Finally, escalating doses of buprenorphine were administered, which resolved the patient's symptoms, highlighting another case to be added to the growing evidence that opioid withdrawals precipitated by buprenorphine can and should be treated with escalating doses of buprenorphine.

Keywords: buprenorphine; opiate withdrawal; opioid withdrawals; pain management; suboxone.

PubMed Disclaimer

Conflict of interest statement

Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Similar articles

References

    1. A case of buprenorphine-precipitated withdrawal managed with high-dose buprenorphine. Quattlebaum TH, Kiyokawa M, Murata KA. https://academic.oup.com/fampra/article/39/2/292/6309967 Fam Pract. 2022;24:292–294. - PubMed
    1. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Ma J, Bao YP, Wang RJ, et al. Mol Psychiatry. 2019;24:1868–1883. - PubMed
    1. Fentanyl law enforcement submissions and increases in synthetic opioid-involved overdose deaths - 27 states, 2013-2014. Gladden RM, Martinez P, Seth P. MMWR Morb Mortal Wkly Rep. 2016;65:837–843. - PubMed
    1. Opioid withdrawal precipitated by long-acting antagonists. Kunzler NM, Wightman RS, Nelson LS. J Emerg Med. 2020;58:245–253. - PubMed
    1. What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size. Keyes KM, Rutherford C, Hamilton A, et al. Drug Alcohol Depend Rep. 2022;3:100052. - PMC - PubMed

Publication types

LinkOut - more resources